A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia
NCT00154258 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19
Last updated 2020-09-24
Summary
Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long term treatment of clozapine in patients with treatment-resistant schizophrenia.
Conditions
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-04-30
- Primary Completion
- 2009-12-31
- Completion
- 2009-12-31
More Related Trials
-
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00103571 ·Status: COMPLETED ·Phase: PHASE4
-
Treating Drug-Resistant Childhood Schizophrenia
NCT00048828 ·Status: COMPLETED ·Phase: PHASE4
-
Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia
NCT00179231 ·Status: COMPLETED ·Phase: NA
-
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
NCT01244828 ·Status: COMPLETED ·Phase: PHASE3
-
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
NCT00051298 ·Status: COMPLETED ·Phase: PHASE3
-
Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder
NCT00501618 ·Status: COMPLETED ·Phase: PHASE4
-
Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)
NCT02404155 ·Status: COMPLETED ·Phase: NA
-
Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder
NCT00480571 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
NCT00345033 ·Status: COMPLETED ·Phase: PHASE4
-
Phase IIA Study in Patients With Schizophrenia
NCT00686998 ·Status: COMPLETED ·Phase: PHASE2
-
Optimization of Treatment and Management of Schizophrenia in Europe
NCT01248195 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease
NCT00004826 ·Status: COMPLETED ·Phase: NA
-
Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder
NCT02562287 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of the Effect of Dosing on Clozapine Levels
NCT02286206 ·Status: WITHDRAWN ·Phase: PHASE4
-
Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)
NCT00156091 ·Status: COMPLETED ·Phase: PHASE3
-
Minocycline Augmentation to Clozapine
NCT02124811 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00088049 ·Status: COMPLETED ·Phase: PHASE4
-
Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics
NCT00485498 ·Status: COMPLETED ·Phase: PHASE4
-
Characterizing Response to Antipsychotics in Schizophrenia
NCT06159322 ·Status: RECRUITING
-
Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18
NCT04849026 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00001656 ·Status: COMPLETED ·Phase: PHASE4
-
Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia
NCT01246232 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
NCT00191555 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)
NCT00151424 ·Status: COMPLETED ·Phase: PHASE3
-
To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00007774 ·Status: COMPLETED ·Phase: PHASE4